Inhaled and Intranasal Products Contract Service Providers Market

Comments · 532 Views

As the figure represents, more than 70 % of the companies which offer contract manufacturing services

During our research, we were able to capture more than 110 players, which claim to offer services related to inhaled and intranasal drug products.

 

Amongst the total players having capability to offer services of inhaled and intranasal drugs products, most of the players engaged in this domain are mid-sized firms. Of these, most of companies have been established before 2001. This is followed by the large firms of which, recently established large firms are (in alphabetical order) Kindeva Drug Delivery (2020) and Mapaex (2016). 

 

A detailed information visit this https://www.rootsanalysis.com/reports/inhaled-and-intranasal-products.html

 

Further, as can be observed from the figure, 39% companies claim to have the required capabilities to provide formulation development and manufacturing services, this is followed by 37% players offering stability testing services. Moreover, 25% players claim to offer process development and particle engineering services. It is worth highlighting that, of the total companies offering manufacturing services, close to 30% offer services at all scales of operation.

 

As the figure represents, more than 70 % of the companies which offer contract manufacturing services, includes majority of mid-sized players (26%), followed by small-sized (24%) and large players (21%).  Similarly, more than 20% of the companies offer contract research services, of which around 9% of the players are mid-sized firms, followed by small-sized (6%) and large (6%) firms. Further, 8% of the remaining services providers offer both contract manufacturing and contract research services, including large and small-sized firms (4% each).

 

Majority of the companies (42%) offer liquid-based formulation of the drug, followed by 22% companies offering powder-based and aerosol-based formulations, each. Further, nasal sprays was found to be the most common dosage form, used by close to 60% companies as a means of drug delivery. This is followed by companies using MDI and DPI dosage forms (39 each). The other dosage forms preferred by the inhaled and intranasal drug product service providers include nebulizers, offered by 26% companies.

 

To request a sample copy / brochure of this report, please visit this

 

https://www.rootsanalysis.com/reports/inhaled-and-intranasal-products/request-sample.html

 

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

Medium - https://medium.com/@RootsAnalysis

Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/

Quora - https://rootsanalysisinsights.quora.com/

Comments